Dawn I. Velligan

9.5k total citations · 3 hit papers
186 papers, 7.1k citations indexed

About

Dawn I. Velligan is a scholar working on Psychiatry and Mental health, Philosophy and Clinical Psychology. According to data from OpenAlex, Dawn I. Velligan has authored 186 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 137 papers in Psychiatry and Mental health, 56 papers in Philosophy and 51 papers in Clinical Psychology. Recurrent topics in Dawn I. Velligan's work include Schizophrenia research and treatment (130 papers), Mental Health and Psychiatry (56 papers) and Bipolar Disorder and Treatment (32 papers). Dawn I. Velligan is often cited by papers focused on Schizophrenia research and treatment (130 papers), Mental Health and Psychiatry (56 papers) and Bipolar Disorder and Treatment (32 papers). Dawn I. Velligan collaborates with scholars based in United States, United Kingdom and Canada. Dawn I. Velligan's co-authors include Alexander L. Miller, Martha Sajatovic, John P. Docherty, Peter J. Weiden, David C. Glahn, Roderick K. Mahurin, Carrie E. Bearden, Jennifer H. Barrett, Philip D. Harvey and Natalie Maples and has published in prestigious journals such as SHILAP Revista de lepidopterología, American Journal of Psychiatry and Biological Psychiatry.

In The Last Decade

Dawn I. Velligan

175 papers receiving 6.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Self-report measures of medication adherence behavior: recommendations on optimal use

2015 550 citations Dawn I. Velligan et al. profile →
The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.

2009 507 citations Dawn I. Velligan, Martha Sajatovic et al. PubMed profile →
The Epidemiology and Global Burden of Schizophrenia

2023 64 citations Dawn I. Velligan, Sanjai Rao The Journal of Clinical Psychiatry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dawn I. Velligan United States	45	4.9k	1.7k	1.2k	1.2k	866	186	7.1k
Alexander L. Miller United States	44	3.7k 0.8×	1.1k 0.6×	633 0.5×	962 0.8×	675 0.8×	145	6.0k
Svein Friis Norway	54	6.1k 1.2×	4.2k 2.4×	745 0.6×	2.4k 2.0×	1.4k 1.6×	241	9.2k
Martha Sajatovic United States	42	5.4k 1.1×	1.7k 1.0×	384 0.3×	356 0.3×	789 0.9×	358	7.8k
Joanne B. Severe United States	23	7.5k 1.5×	3.6k 2.1×	1.2k 1.0×	1.2k 1.0×	759 0.9×	39	9.9k
Pierre‐Michel Llorca France	41	3.0k 0.6×	1.7k 1.0×	567 0.5×	657 0.6×	623 0.7×	307	6.3k
A. George Awad Canada	35	3.6k 0.7×	1.7k 1.0×	272 0.2×	948 0.8×	757 0.9×	80	4.6k
Hélène Verdoux France	38	3.8k 0.8×	2.0k 1.1×	696 0.6×	1.1k 0.9×	867 1.0×	176	6.3k
Dieter Naber Germany	55	6.5k 1.3×	2.4k 1.4×	1.2k 1.0×	1.9k 1.6×	1.1k 1.3×	333	10.4k
Ana González‐Pinto Spain	54	6.7k 1.4×	2.3k 1.3×	1.1k 0.9×	500 0.4×	589 0.7×	376	10.0k
John P. Docherty United States	34	2.8k 0.6×	1.8k 1.0×	213 0.2×	678 0.6×	629 0.7×	101	5.1k

Countries citing papers authored by Dawn I. Velligan

Since Specialization

Citations

This map shows the geographic impact of Dawn I. Velligan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dawn I. Velligan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dawn I. Velligan more than expected).

Fields of papers citing papers by Dawn I. Velligan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dawn I. Velligan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dawn I. Velligan. The network helps show where Dawn I. Velligan may publish in the future.

Co-authorship network of co-authors of Dawn I. Velligan

This figure shows the co-authorship network connecting the top 25 collaborators of Dawn I. Velligan. A scholar is included among the top collaborators of Dawn I. Velligan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dawn I. Velligan. Dawn I. Velligan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Velligan, Dawn I., et al.. (2025). Preferences for Selecting and Initiating Long-Acting Injectable Antipsychotic Agents for the Treatment of Patients With Schizophrenia: Results From the US DECIDE Survey. Schizophrenia Bulletin Open. 6(1). sgaf001–sgaf001. 2 indexed citations

Nuechterlein, Keith H., Henry A. Nasrallah, & Dawn I. Velligan. (2024). Measuring Cognitive Impairments Associated With Schizophrenia in Clinical Practice: Overview of Current Challenges and Future Opportunities. Schizophrenia Bulletin. 51(2). 401–421. 8 indexed citations

Teigland, Christie, et al.. (2024). Relationship between social determinants of health and hospitalizations and costs in patients with major depressive disorder. Journal of Managed Care & Specialty Pharmacy. 30(9). 978–990. 1 indexed citations

Daniel, David G., Alex S. Cohen, Philip D. Harvey, et al.. (2024). Rationale and Challenges for a New Instrument for Remote Measurement of Negative Symptoms. Schizophrenia Bulletin Open. 5(1). sgae027–sgae027. 2 indexed citations

Velligan, Dawn I. & Sanjai Rao. (2023). The Epidemiology and Global Burden of Schizophrenia. The Journal of Clinical Psychiatry. 84(1). 64 indexed citations breakdown →

Haider, Batool A, Amy K. O’Sullivan, Leona Bessonova, et al.. (2023). Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic. Neuropsychiatric Disease and Treatment. Volume 19. 623–634. 1 indexed citations

Daniel, David G., Alex S. Cohen, Dawn I. Velligan, et al.. (2023). Remote Assessment of Negative Symptoms of Schizophrenia. Schizophrenia Bulletin Open. 4(1). sgad001–sgad001. 5 indexed citations

Ruetsch, Charles, et al.. (2022). The effect of objectively collected medication adherence information on bipolar I and major depressive disorder treatment decisions: A randomized case vignette study of psychiatric clinicians. Journal of Affective Disorders Reports. 9. 100344–100344.

Hamilton, Jane, Salih Selek, Kelly L. Wirfel, et al.. (2022). Patient and Provider Perspectives on Medication Non-adherence Among Patients with Depression and/or Diabetes in Diverse Community Settings – A Qualitative Analysis. Patient Preference and Adherence. Volume 16. 1581–1594. 8 indexed citations

10.

Liberman, Joshua N., Dawn I. Velligan, Delbert G. Robinson, et al.. (2022). Mental Health Care Provider's Perspectives Toward Adopting a Novel Technology to Improve Medication Adherence. SHILAP Revista de lepidopterología. 4(2). 61–70. 3 indexed citations

11.

Peterson, Alan L., Patricia A. Resick, Jim Mintz, et al.. (2018). Design of a clinical effectiveness trial of in-home cognitive processing therapy for combat-related PTSD. Contemporary Clinical Trials. 73. 27–35. 4 indexed citations

12.

Walss‐Bass, Consuelo, G.L. Lokesh, David G. Gorenstein, et al.. (2018). X-Aptamer Technology Identifies C4A and ApoB in Blood as Potential Markers for Schizophrenia. PubMed. 5(1). 52–59. 19 indexed citations

13.

Velligan, Dawn I., William T. Carpenter, Heidi C. Waters, et al.. (2017). Relapse Risk Assessment for Schizophrenia Patients (RASP): A New Self-Report Screening Tool. Clinical Schizophrenia & Related Psychoses. 11(4). 224–235. 1 indexed citations

14.

Velligan, Dawn I. & Larry Alphs. (2014). Negative Symptoms in Schizophrenia: An Update on Identification and Treatment. The Psychiatric times. 31(11). 8 indexed citations

15.

Kiosses, Dimitris N., Linda Teri, Dawn I. Velligan, & George S. Alexopoulos. (2010). A home‐delivered intervention for depressed, cognitively impaired, disabled elders. International Journal of Geriatric Psychiatry. 26(3). 256–262. 24 indexed citations

16.

Velligan, Dawn I., et al.. (2010). Cognitive behavioral therapy for schizophrenia: A review of recent literature and meta-analyses. 51(2). 85–94. 1 indexed citations

17.

Velligan, Dawn I. & Larry Alphs. (2008). Negative Symptoms in Schizophrenia: The Importance of Identification and Treatment. The Psychiatric times. 25(3). 18 indexed citations

18.

Glahn, David C. & Dawn I. Velligan. (2007). Cognitive Impairment in Patients With Bipolar Disorder: Effect on Psychosocial Functioning. The Psychiatric times. 24(6). 26–28. 1 indexed citations

19.

Velligan, Dawn I. & Alexander L. Miller. (1999). Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment.. PubMed. 60 Suppl 23. 25–8. 59 indexed citations

20.

Velligan, Dawn I., et al.. (1990). Can Communication Deviance Be Measured in a Family Problem‐Solving Interaction?. Family Process. 29(2). 213–226. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact